linjc16/ctgov huggingface dataset:
Prognostic Assessment of Contrast Echocardiography (PACE Study)

Study Overview
=================
Brief Summary
-----------------
This study will demonstrate whether patients with prognostically-significant myocardial abnormalities detected with AI-700 contrast ECHO have a rate of cardiac death or MI that is higher than that of patients with normal AI-700 contrast ECHO.

Detailed Description
-----------------
This observational study will investigate the ability of AI-700 contrast ECHO to predict risk of future cardiovascular events occurring in patients who had a recent history of chest pain at the time of ECHO evaluation. Eligible patients were enrolled in either AI-700-32 or AI-700-33, which are completed Phase 3 international, multicenter, open-label, dual-injection studies of the myocardial imaging capabilities and safety of AI-700 administered intravenously in patients with chest pain. In the course of these Phase 3 studies, patients were evaluated with AI-700 contrast ECHO. In addition, eligible patients were to have had an evaluable pharmacologic stress-induced AI-700 ECHO assessment as part of AI-700-32 or AI-700-33.

Official Title
-----------------
Prognostic Assessment of Contrast Echocardiography (PACE Study): An Observational Follow-up Study of Patients With Chest Pain Evaluated With AI-700 Contrast Echocardiography

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Eligible patients were enrolled in either AI-700-32 or AI-700-33.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome variable is the time to first occurrence of the composite outcome (death or confirmed non fatal MI). |  | The time between AI 700 ECHO and outcomes data collection will be ≥12 months with an expected average follow-up period of 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Certain secondary analyses will include revascularizations and CHF. |  | The time between AI 700 ECHO and outcomes data collection will be ≥12 months with an expected average follow-up period of 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary artery disease, echocardiography, cardiac imaging, heart disease, ultrasound contrast agent, prognosis
Prospective Observational Study and Biobank CKIO

Study Overview
=================
Brief Summary
-----------------
Prospective observational study and biobank in all persons referred to CKIO Patient involvement and quality of life Population characteristics regarding hormone levels, safety parameters and clinical outcome before and after gender affirming hormone treatment.

Detailed Description
-----------------
This is a prospective observational cohort study including all patients referred to the Center of Gender Identity Odense. The purpose is to follow patients yearly to observe patient reported outcomes and control the quality and effects of the clinical treatment.

Official Title
-----------------
Prospective Observational Study and Biobank in All Persons Referred to Center of Gender Identity Odense University Hospital (CKIO)/Body Identity Clinic

Conditions
-----------------
Transgender

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All Individuals with gender dysforia who are referred to Center of Gender Identity Odense Age 18+ Exclusion Criteria: °There are no exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Transgender individuals<br>All transgender individuals referred to center of gender identity Odense | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient reported outcomes (PRO) | Questionnaires | Every 52 weeks | 
| Hormone levels | Blood samples | Every 52 weeks | 
| Safety parameters | Blood samples | Every 52 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure | Blood pressure measured in a sitting position | Every 52 weeks | 
| Body mass index | Body mass index calculated from height an weight | Every 52 weeks | 
| Body weight | Body weight measured on a scale in kilogram | Every 52 weeks | 
| Hair cortisol | Hair samples 3 mm thick from the back of the head | Every 52 weeks | 
| Cortisol metabolism | 24 hour urine samples | Every 52 weeks | 
| Spirometry | Forced vital capacity is measured by a spirometer | Every 52 weeks |
A Prospective Study of Factors Related to Exacerbation and Mortality of Non-cystic Fibrosis Bronchiectasis in Hong Kong

Study Overview
=================
Brief Summary
-----------------
Bronchiectasis is associated with repeated exacerbations which occurs at rates of 1.5-6.5 per patients per year, and are associated with an increased risk of admission and readmission to hospital, and high health care costs. In a local study carried out more than 10 years ago, idiopathic disease dominates and patients with bronchiectasis are mainly female with high hospitalization and mortality rates; 21.9 cases per 100,000 and 2.7 cases per 100,000 respectively. Moreover, exacerbation characterized by increases in symptoms requiring antibiotic treatment is associated with disease progression and significant mortality. Updated prevalence of this disease with the characteristics of etiology, clinical presentation and outcomes are needed to guide further management plan.

Official Title
-----------------
A Prospective Study of Factors Related to Exacerbation and Mortality of Non-cystic Fibrosis Bronchiectasis in Hong Kong

Conditions
-----------------
Bronchiectasis Adult

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 18 years or older Clinically stable for at least 4 weeks prior to enrollment (defined as no symptoms of exacerbation, no requirement for supplemental antibiotic therapy) Diagnosis of bronchiectasis defined by high-resolution computed tomography scan Exclusion Criteria: History of cystic fibrosis; hypogammaglobulinemia; allergic bronchopulmonary aspergilosis Those who are unable to give consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of bronchiectasis exacerbation |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality rate |  | 5 years |
Elastography Interest in the Management of Thyroid Nodules

Study Overview
=================
Brief Summary
-----------------
Define an ultrasound/elastography benignity criteria in strategy management of a patient population carries one or more thyroid nodules.

Official Title
-----------------
ShearWave Elastography Interest in the Management of Thyroid Nodules

Conditions
-----------------
Thyroid Nodules

Intervention / Treatment
-----------------
* Device: Medical ultrasound device (ShearWave system)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient aged over 18 years old Patient affiliated to social security or similarly regime Patients referred for fine needle aspiration or surgery with one or more thyroid nodules Exclusion Criteria: Patients with too much thyroid nodules or topography too imprecise to allow unambiguous correlation between echo/elastography data and histology/cytology data Patients withan echography/elastography indications cons Pregnant women and lactating mothers Adult unable to express their consent Ward of court or under guardianship Person under legal protection Person deprived of freedom by judicial or administrative decision Person hospitalized without their consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: echography/elastography<br> | Device: Medical ultrasound device (ShearWave system)<br>* Echography (all modes) and elastography ShearWave system<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Defined echo/elastography benignity criteria | For ultrasound and elastography benignity criteria which will be retained, outcome focus on cytoponctions number for benin nodules can be avoided by taking into account this benign criteria | two and half years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the diagnostic performance of elastography ShearWave for characterization of thyroid nodules in a population of patients referred for needle biopsy or surgery nodule thyroid | ROC curves for performance of ultrasound, elastography and their coupling, compared to the reference cytology / histology. | two and half years | 
| Assessing the use of elastography in clinical practice |  | two and half years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Echography, Elastography, Thyroid nodules, Needles punction, Thyroid surgery, Patients with thyroids nodules
The Prognosis of Graft Using Plastic Cannula in Hemodialysis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the complication of the puncture related complication in AVG (arteriovenous graft) such as pseudoaneurysm and hematoma, and the dialysis adequacy using plastic cannula versus metal needle in hemodialysis patients

Detailed Description
-----------------
Ultrasonography is performed to determine the maturity of vascular access 4 weeks after AVG creation. The first puncture is performed with plastic cannula or metal needle when it is judged that the blood vessel has matured. Four skilled nurses perform vascular access puncture with plastic or metal needle Ultrasound are used to evaluate and record the complications related to the puncture in plastic or metal needle group every month. Complications and dialysis adequacy between the two groups will be evaluated after 6 months

Official Title
-----------------
A Prospective Study of the Prognosis of Graft With Plastic Cannula in Hemodialysis

Conditions
-----------------
End Stage Renal Failure on Dialysis

Intervention / Treatment
-----------------
* Device: Plastic cannula


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients receiving hemodialysis treatment using AVG Exclusion Criteria: Age under 20 years old or over 75 years old Abnormal skin condition using immunosuppressants such as steroids. Skin disorder Metal allergy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Metal needle gruop<br>puncture using metal needle | |
| Experimental: plastic cannula<br>puncture using plastic cannula | Device: Plastic cannula<br>* puncture using plastic cannula<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of pseudoaneurysm | critical puncture related complication in AVG | Incidence of pseudoaneurysm at 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| punctutre related complication | hematoma, inflitration, thrombus | Monthly for 6 months. | 
| Dialysis adeqaucy | Kt/V by serum test in two groups | Monthly for 6 months. |
The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning

Study Overview
=================
Brief Summary
-----------------
Based on the gastric cancer database established earlier, this project explored the PG standard suitable for Chinese people, and further explored the establishment of machine learning model to stratify gastric cancer risk in the population, guide the frequency of gastroscopy screening, and extract important gastric cancer risk factors from it.Establish electronic health records of gastric organs, track the development and outcome of gastric diseases through deep learning method, in order to predict the development and outcome of gastric diseases;Then, the simulation hypothesis deductive method is used to compare the outcomes that may be caused by different lifestyles with the help of deep learning model, so as to guide patients to develop a better lifestyle and explore the establishment of health management paths for gastric cancer patients and high-risk groups in China.

Official Title
-----------------
The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning

Conditions
-----------------
Gastric Cancer, Precancerous Lesion, Mechine Learning

Intervention / Treatment
-----------------
* Other: pepsinogen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1） intention to undergo gastroscopy during health checkup examination; and 2) 25-75 years of age Exclusion Criteria: 1) a history of gastric ulcer, gastric polyp, or GC; 2) a history of gastrectomy; 3) treatment with a proton pump inhibitor in the last month; 4) contraindications to gastroscopy; 5) a history of Hp eradication; 6) a history of abdominal pain, abdominal distention, belching, acid reflux, nausea and other digestive tract symptoms within 1 month or 67) incomplete data.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| non-atrophic gastritis<br>OLGA-0 group；OLGA (Operative Link on Gastritis Assessment) | |
| mild-moderate atrophic gastritis<br>OLGA I-II group；OLGA (Operative Link on Gastritis Assessment) | |
| severe atrophic gastritis<br>OLGA III-IV group；OLGA (Operative Link on Gastritis Assessment) | Other: pepsinogen<br>* diagnostic value of pepsinogen for severe atrophy and gastric cancer<br>|
| gastric cancer<br>gastric cancer | Other: pepsinogen<br>* diagnostic value of pepsinogen for severe atrophy and gastric cancer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pepsinogen value for precanceous lesion and Gastric cancer | pepsinogen value for precanceous lesion and Gastric cancer | 1 year |
Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief?

Study Overview
=================
Brief Summary
-----------------
The Surgical Outpatient Clinic at Molde Hospital has since 2015 offered specialized treatment for patients with diabetic foot ulcers. This treatment is given by an interdisciplinary diabetic foot ulcer team. The standard treatment for diabetic foot ulcers is relief, a method with good results. Although the treatment as usual gives good results, the team wants to optimize this treatment. By using custom felt relief for each patient, the treatment period might be reduced considerably. The aim of this study is therefore to investigate whether custom felt relief gives shorter processing time compared to standard relief treatment.

Official Title
-----------------
Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief?

Conditions
-----------------
Diabetic Foot Ulcer

Intervention / Treatment
-----------------
* Procedure: custom felt relief
* Procedure: standard relief treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed with Diabetes Mellitus Type 1 or 2 has neuropathic wounds under the foot understands and speaks Norwegian well competent to give consent Exclusion Criteria: responds to the filament glue and/or the tape used in treatment in need of vascular surgery intervention to be admitted to the hospital in need of intravenously administered antibiotics due to wound infection.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: block randomization
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: felt relief<br>custom felt relief | Procedure: custom felt relief<br>* Felt is adjusted to the wound by cutting it in different ways and layers once every week<br>|
| Active Comparator: treatment as usual<br>standard treatment usually provided by the Surgical Outpatient Clinic | Procedure: standard relief treatment<br>* Felt in the shape of a letter U is put around the wound once every week.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| wound healing time in weeks | from the patients first visit (when the first felt dressing is applied) until the wound is healed | 2-8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bandages, Wound Healing, Time, Relief
Bone Mineral Density (BMD) in HIV Infection

Study Overview
=================
Brief Summary
-----------------
Osteopenia and osteoporosis are increasingly reported in HIV-infected patients, and appear to be more frequent than in general population. However, pathogenesis remains unclear, and published studies still give non concordant results. We therefore started a prospective study, to assess the potential role of ARV in the occurrence of osteopenia and osteoporosis. BMD evolution over a 2-years period of follow-up, will be compared between patients starting ARV therapy, and subjects without HAART (no indication of treatment). A correlation between BMD and several factors will be looked at (see below). This study with individual direct benefice, is conducted in 3 outpatients clinics (Strasbourg, Colmar, Mulhouse) in collaboration with the rheumatologic teams. 60 patients are planned to be included over a 3-years inclusion period

Official Title
-----------------
Osteopenia and Osteoporosis in HIV Infection. Prospective BMD Measurement in Antiretroviral (ARV) Treated and Untreated HIV-1 Infected Patients

Conditions
-----------------
Osteoporosis, Osteopenia

Intervention / Treatment
-----------------
* Procedure: BMD Measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV-1 infected men, Caucasian, age > 18 years, ARV-naïve Exclusion Criteria: HIV-infected women, subjects < 18 years, non-Caucasian men, ARV-experienced patients, subjects not able or willing to give informed consent, endocrine disease or treatment which could affect bone metabolism

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: BMD Measurement|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BMD evolution and modification during 2 years of follow-up, compared between treated and untreated subjects |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BMD (baseline, and at 2 years) according to: |  |  | 
| - calcium intake, physical activity, |  |  | 
| - CD4 lymphocyte count, HIV viral load, |  |  | 
| - bone metabolism biological markers (osteocalcine, C telopeptide collagen type I in urine), |  |  | 
| - leptine, parathormone, 25 OH D3 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteopenia, osteoporosis, bone mineral density, HIV infection, bone metabolism, Treatment Naive